Jazz Pharmaceuticals (JAZZ) Stock: Buy, Sell, or Hold?
JAZZ - Jazz Pharmaceuticals, Inc.
$233.01
1.49 (0.64%)
▲
5d:
-1.38%
30d:
-4.39%
90d:
-4.3%
HOLD
MODERATE Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When JAZZ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: JAZZ is fairly valued with market pricing in 2.2% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: JAZZ is fairly valued with market pricing in 2.2% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$260.46
Based on 3.6% avg growth
INTRINSIC VALUE TODAY
$161.73
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: JAZZ is currently trading at $233.01, which is considered oversold relative to its 30-day fair value range of $239.75 to $251.53. The stock's valuation (Forward PE: 9.1) is in line with its historical norms (8.5). At these levels, the market is pricing in 2.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, JAZZ is in a uptrend. The price is currently testing key support at $229.16. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 57/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $292.81 (+25.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, JAZZ is in a uptrend. The price is currently testing key support at $229.16. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 57/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $292.81 (+25.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$239.75 -
$251.53
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
80.5%
Protect Your Profits
Holding JAZZ? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (57/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 25.7% below Wall St target ($292.81)
- NEUTRAL: Market pricing in 2.2% annual earnings growth - fairly valued
- NEUTRAL: Bottoming setup forming (57/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$239.75 -
$251.53
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$229.16
Resistance Level
$244.55
Current Trend
Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.05
Wall Street Target
$292.81
(+25.7%)
Revenue Growth (YoY)
15.5%
Earnings Growth (YoY)
3.2%
Profit Margin
20.4%
Valuation Premium vs History
+2.2% premium
PE vs Historical
9.1 vs 8.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.2%
(market-implied from PE analysis)
1-Year Target
$238.14
(+2%)
2-Year Target
$243.38
(+4%)
3-Year Target
$248.73
(+7%)
3-Yr Target (if PE normalizes)
(PE: 9→9)
PE COMPRESSION
$233.54
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 3.1%)
$576.11
(+147%)
Base:
(SPY PE: 9.1, Growth: 3.1%)
$255.66
(+10%)
Bear:
(PE: 7.7, Growth: 3.1%)
$217.31
(-7%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 15.85 | Current EPS (TTM): $14.61
Bull Case
$448.66
(+93%)
Analyst growth 76.2%, PE expands to 17.4
Base Case
$407.87
(+75%)
Market implied 76.2%, PE stable at 15.9
Bear Case
$157.43
(-32%)
Severe decline -20.0%, PE contracts to 13.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 02, 2026 3:32 AM ET
Data refreshes hourly during market hours. Next update: 4:32 AM
Data refreshes hourly during market hours. Next update: 4:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JAZZ showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 59 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$47 | 55 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 45 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$139 | 66 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$118 | 54 HOLD |
Advanced JAZZ Option Strategies
Professional options setups generated by AI based on today's JAZZ price and gamma walls.
